Robert Graor, MD
Cardiovascular Disease · Las Cruces, NMNPI 1114926409
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,102 of the $10,735 with a category attached, or 66.2%. 28 manufacturers reported payments, led by Abbott at 36.6% of the total. 2025 is the largest year on record at $3,261, 2.1 times the $1,523 reported in 2019. Among cardiovascular disease clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $37.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Abiomed$3K
- Medtronic$2K
- Boston Scientific$191
- Amgen$182
- Shockwave Medical, Inc$178
- plus $1K from 22 others
What the payments were for
- Travel & lodging$3,58833%
- Food & beverage$7,10266%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 115 | $3,928 |
| Abiomed | 81 | $3,383 |
| Medtronic(2 entities) | 18 | $1,679 |
| Boston Scientific | 9 | $191 |
| Amgen | 11 | $182 |
| Shockwave Medical, Inc | 2 | $178 |
| Novartis | 6 | $120 |
| Sanofi-aventis U.S. LLC | 7 | $114 |
| Edwards Lifesciences | 1 | $110 |
| Cardiovascular Systems Inc. | 3 | $103 |
| E.r. Squibb & Sons, L.L.C. | 4 | $97 |
| Amarin Pharma, Inc. | 5 | $89 |
| Medline Industries LP | 1 | $76 |
| Chiesi USA, Inc. | 5 | $68 |
| Cvrx, Inc. | 3 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $45 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $38 |
| Inari Medical, Inc. | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $36 |
| Boehringer Ingelheim | 2 | $36 |
| AstraZeneca | 2 | $32 |
| Davol Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Biosense Webster, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,795
- Resolute$1,238
- Impella$986
- Edwards SAPIEN 3 Transcatheter Heart Valve$110
How this compares
$10,735 in reported general payments places this provider in the 90th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 298 | $397,817 |
| EntrestoSacubitril/Valsartan | 147 | $221,359 |
| XareltoRivaroxaban | 42 | $53,875 |
| Repatha SureclickEvolocumab | 52 | $45,483 |
| Flecainide Acetate | 176 | $8,196 |
| Prasugrel Hcl | 40 | $6,215 |
| ClopidogrelClopidogrel Bisulfate | 468 | $5,734 |
| Metoprolol Succinate | 260 | $4,129 |
| Amiodarone Hcl | 139 | $4,001 |
| Atorvastatin Calcium | 280 | $3,325 |
| Valsartan | 134 | $3,164 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 96 | $3,090 |
| Clonidine | 12 | $2,485 |
| Potassium Chloride | 133 | $2,267 |
| Amlodipine Besylate | 261 | $2,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $397,817298 claims |
| NovartisEntresto | $120 | $221,359147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Las Cruces
- Jose Rodriguez ArciniegaLas Cruces$24K
- Muhammad AnwarLas Cruces$14K
- Craig CannonLas Cruces$9K
- Terry BoulwareLas Cruces$5K
- Angelica MottaLas Cruces$2K
- Guido LeonLas Cruces$1K
- Abinash AchrekarAlbuquerque$88K
- Suresh NeelagaruChama$46K
- Adam BanksAlbuquerque$38K
- Stacey CleggAlbuquerque$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.